Elan v. Teva Pharmaceuticals USA, Inc. (Dexmethylphenidate ER)

Our client filed an ANDA including a Paragraph IV challenge of Elan’s patents covering the formulation of Celgene’s Focalin® (dexmethylphenidate) extended release tablets. Carlson Caspers represented Teva in the ensuing Hatch-Waxman patent litigation, and negotiated a settlement favorable to our client.